C
Celadon Pharmaceuticals PLC
LSE:CEL
Celadon Pharmaceuticals PLC
LSE:CEL
Price:
13.4
GBX
Market Closed
Market Cap:
£9.2m
Income Statement
Earnings Waterfall
Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals PLC
Income Statement
Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals PLC
Currency: GBP
| Feb-2021 | Aug-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
0
|
0
|
0
|
4
|
4
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
+465%
|
1
+10 502%
|
0
-98%
|
371
+1 793 166%
|
0
-100%
|
37
+28 603%
|
37
-2%
|
37
+2%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
0
|
0
|
(2)
|
(2)
|
(5)
|
(6)
|
(5)
|
(5)
|
0
|
0
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
(2)
N/A
|
(2)
+24%
|
(5)
-171%
|
(6)
-23%
|
(5)
+11%
|
(4)
+17%
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(0)
|
(0)
|
(0)
|
(1)
|
(668)
|
(1)
|
(588)
|
(1)
|
(504)
|
(252)
|
(384)
|
|
| Selling, General & Administrative |
(0)
|
(0)
|
0
|
0
|
(213)
|
0
|
(206)
|
0
|
(183)
|
(95)
|
(159)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
(462)
|
0
|
(387)
|
0
|
(321)
|
(155)
|
(225)
|
|
| Depreciation & Amortization |
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
7
|
0
|
7
|
0
|
0
|
(2)
|
0
|
|
| Operating Income |
(0)
N/A
|
(0)
-120%
|
(3)
-471%
|
(3)
+5%
|
(672)
-25 956%
|
(7)
+99%
|
(222)
-3 267%
|
(5)
+98%
|
(467)
-9 207%
|
(215)
+54%
|
(346)
-61%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
0
|
0
|
(1)
|
(4)
|
(4)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
(0)
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
(96)
|
|
| Total Other Income |
0
|
0
|
0
|
(6)
|
27
|
(1)
|
72
|
0
|
104
|
41
|
64
|
|
| Pre-Tax Income |
(0)
N/A
|
(0)
-55%
|
(5)
-914%
|
(14)
-191%
|
(651)
-4 559%
|
(9)
+99%
|
(151)
-1 557%
|
(5)
+96%
|
(363)
-6 502%
|
(174)
+52%
|
(379)
-118%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
1
|
(3)
|
0
|
(4)
|
(2)
|
(3)
|
|
| Income from Continuing Operations |
(0)
|
(0)
|
(5)
|
(14)
|
(650)
|
(8)
|
(154)
|
(5)
|
(366)
|
(176)
|
(382)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(0)
N/A
|
(0)
-55%
|
(5)
-878%
|
(14)
-197%
|
(650)
-4 629%
|
(8)
+99%
|
(154)
-1 806%
|
(5)
+97%
|
(366)
-6 900%
|
(176)
+52%
|
(382)
-117%
|
|
| EPS (Diluted) |
-0.05
N/A
|
-0.06
-20%
|
-0.1
-67%
|
-0.26
-160%
|
-8.36
-3 115%
|
-0.13
+98%
|
-1.94
-1 392%
|
-0.08
+96%
|
-4.34
-5 325%
|
-2.06
+53%
|
-4.38
-113%
|
|
Switch to:
Switch to:
See Also
Discover More
